The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.444%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 47.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

13 Jan 2021 07:00

RNS Number : 4664L
Benchmark Holdings PLC
13 January 2021
 

13 January 2021

Benchmark Holdings plc

("Benchmark" or "the Company")

Payment of contingent consideration following achievement of milestones

 

Issue of Equity

 

Benchmark (AIM: BMK), the aquaculture health, nutrition and genetics business, announces that further to the acquisition of aquaculture breeding programmes centred on shrimp from Centro de Investigación de la Acuicultura de Colombia Ceniacua on 11 August 2016, $450,000 of contingent consideration is payable following the satisfaction of specified operational milestones (the "Contingent Consideration").

At the Company's discretion, the Contingent Consideration is payable in ordinary shares in the Company using an agreed formula. The Company has therefore issued 536,272 Ordinary Shares of 0.1p each in the capital of the Company (the "New Ordinary Shares").

Application has been made for the New Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading will commence at 8:00am on 18 January 2021. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 668,927,771. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Trond Williksen, CEO, commented:

 

"The payment of the contingent consideration is a reflection of the success of our shrimp genetics operations since the acquisition was made. Through a team of leading geneticists, we successfully expanded our genetics business into shrimp and developed a Specified Pathogen Resistant SPR shrimp which will be rolled out in Asia in the coming year.

 

"Specialist genetics are a significant driver of sustainable production. The introduction of SPR shrimp will help improve sustainability in shrimp production and is an important growth vector for Benchmark, as we remain focused on becoming a profitable, cash generative Group."

 

 Enquiries

For further information, please contact:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

 

Septima Maguire, CFO

 

Ivonne Cantu, Investor Relations

 

 

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 

 

 

MHP Communications

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver, Charlie Protheroe

benchmark@mhpc.com

 

 

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFEFUEEFSEFF
Date   Source Headline
30th Sep 20207:00 amRNSTotal Voting Rights
29th Sep 20207:00 amRNSHolding(s) in Company
21st Sep 20207:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
11th Sep 20205:58 pmRNSHolding(s) in Company
10th Sep 20209:15 amRNSPositive Opinion from the EMA on BMK08
4th Sep 20207:00 amRNSDirector/PDMR Shareholding
28th Aug 20207:00 amRNSTotal Voting Rights
28th Aug 20207:00 amRNSQ3 Results
21st Aug 20207:00 amRNSNotice of Q3 Results
31st Jul 202011:17 amRNSCompletion of sale of vaccine facility
31st Jul 20207:00 amRNSTotal Voting Rights
23rd Jul 202011:05 amRNSSale of vaccine manufacturing assets
1st Jul 20207:00 amRNSSale of FishVet
30th Jun 20207:00 amRNSTotal Voting Rights
23rd Jun 20207:00 amRNSSale of Improve International
8th Jun 20204:54 pmRNSDirector/PDMR Shareholding - Replacement
8th Jun 202010:43 amRNSDirector/PDMR Shareholding
5th Jun 20205:50 pmRNSDirector/PDMR Shareholding
29th May 20207:00 amRNSTotal Voting Rights
29th May 20207:00 amRNSSecond Quarter and Interim Results
27th May 20208:30 amRNSEquity Development Results Webinar
19th May 20207:00 amRNSNotice of Q2 and Interim Results
6th May 202012:09 pmRNSHolding(s) in Company
30th Apr 20207:00 amRNSTotal Voting Rights
21st Apr 20207:00 amRNSDirector and Divisional Management Changes
7th Apr 20207:00 amRNSAppointment of Chief Executive Officer
2nd Apr 20207:00 amRNSCovid-19 update
31st Mar 202011:12 amRNSTotal Voting Rights
20th Mar 20207:00 amRNSBlock Listing Six Monthly Review
18th Mar 20207:00 amRNSBlock Admission Application
16th Mar 202012:00 pmRNSDirector Dealings
12th Mar 20201:15 pmRNSResult of AGM
9th Mar 20202:01 pmRNSHolding(s) in Company
9th Mar 20201:46 pmRNSDIRECTOR DEALINGS
28th Feb 20207:00 amRNSTotal Voting Rights
28th Feb 20207:00 amRNSQ1 Results
25th Feb 20209:43 amRNSDIRECTOR SHARE OPTIONS
21st Feb 202010:49 amRNSDirector/PDMR Shareholding
20th Feb 20204:10 pmRNSHolding(s) in Company
20th Feb 20209:15 amRNSHolding(s) in Company
17th Feb 20204:28 pmRNSResult of General Meeting and Total Voting Rights
17th Feb 20207:00 amRNSResult of Open Offer
11th Feb 20207:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
31st Jan 20207:00 amRNSTotal Voting Rights
30th Jan 20202:46 pmRNSTimetable for Placing and Open Offer
30th Jan 20207:00 amRNSPlacing and Open Offer
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20199:06 amRNSSecond Price Monitoring Extn
20th Dec 20199:00 amRNSPrice Monitoring Extension
20th Dec 20197:00 amRNSQ4 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.